Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study. (2018). SKIN The Journal of Cutaneous Medicine, 2(S1), S45. https://doi.org/10.25251/skin.2.supp.45